AI Medical Company VUNO has received a license from the Korean Ministry of Food and Drug Safety for their personal electrocardiogram device.
Called the Hativ Pro, the handheld medical device simply measures the user’s heart rate and sends this data through a connected mobile phone app.
WHY IT IMPORTANT
VUNO has been providing a wide range of medical AI solutions to doctors and medical facilities. After this latest government certification, VUNO can finally move towards delivering AI medical devices to consumers.
With the adoption of MFDS, the company plans to soon launch its integrated health management brand Hativ, featuring AI-powered home medical devices that support consumers’ daily health management and diagnostics. early chronic diseases.
VUNO continues to bolster its medical AI business based on ECG data, which the company claims has “high potential as a biomarker for various cardiovascular diseases”. In Korea, CVDs are the second leading cause of death after cancer with the number of cases increasing each year due to the aging population.
VUNO CEO Lee Ye Ha said: “Through the medical AI project based on ECG data, we will make every effort to reduce cardiovascular disease mortality and contribute to prevention – future direction of the healthcare industry”.
In the future, VUNO plans to release more AI home medical devices to detect major heart diseases.
TREND TO BIGGER
In recent months, VUNO has gathered a number of regulatory approvals to market its AI medical solutions in Korea and the rest of Asia Pacific.
In March, VUNO was approved by the Korean government for VUNO Med LungQuant, an AI-based quantitative CT lung solution for accurate assessment and screening of lung diseases. Last year, it also received an MFDS license for VUNO Med DeepCARSa medical device that uses AI to analyze a person’s risk of cardiac arrest.
During the first half of the year, the company also received market approvals in Thailand, Saudi Arabia and Malaysia for its other VUNO Med services.
